title: Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein.
authors.affiliation: Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France. b-clarivet@chu-montpellier.fr.
authors.forename: B
authors.identifier: http://orcid.org/0000-0003-1723-2927
authors.initials: B
authors.lastname: Clarivet
authors.affiliation: Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France.
authors.forename: P
authors.initials: P
authors.lastname: Robin
authors.affiliation: Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Montpellier University Hospital, Montpellier, France.
authors.forename: Y M
authors.initials: YM
authors.lastname: Pers
authors.affiliation: Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Montpellier University Hospital, Montpellier, France.
authors.forename: R
authors.initials: R
authors.lastname: Ferreira
authors.affiliation: Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France.
authors.forename: J
authors.initials: J
authors.lastname: Lebrun
authors.affiliation: Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Montpellier University Hospital, Montpellier, France.
authors.forename: C
authors.initials: C
authors.lastname: Jorgensen
authors.affiliation: Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France.
authors.forename: D
authors.initials: D
authors.lastname: Hillaire-Buys
authors.affiliation: Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France.
authors.forename: V
authors.initials: V
authors.lastname: Brés
authors.affiliation: Pharmacovigilance Regional Centre, Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France.
authors.forename: J L
authors.initials: JL
authors.lastname: Faillie
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000925:Anticoagulants / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001281:Atrial Fibrillation / Q000188:drug therapy; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D000069604:Dabigatran / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D065666:Mesenteric Ischemia / Q000209:etiology*; D008875:Middle Aged; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D018501:Antirheumatic Agents; D019947:Receptors, Interleukin-6; D003577:Cytochrome P-450 Enzyme System; C502936:tocilizumab; D000069604:Dabigatran